COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAM HAMBURG, Germany and SEATTLE, April 18, 2024 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc ...

#researchneverstops | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance & Guidance - Evotec reported a 14% revenue growth in 9M 2023, reaching €580.1 million compared to €510.8 million in 9M 2022, driven by Precision Medicine and Biologics[19, 29, 43] - Adjusted Group EBITDA increased by 13% to €50.2 million in 9M 2023, compared to €44.6 million in 9M 2022, impacted by missed opportunities in Q2 and normalization in Q3[19, 29] - Just - Evotec Biologics (JEB) revenues grew by over 160%, reaching €74.1 million in 9M 2023, compared to €27.9 million in 9M 2022, boosted by the Sandoz alliance and a second Department of Defense (DoD) contract[19, 29, 43] - The company reaffirms its 2023 revenue guidance at €750-790 million, despite an approximate €70 million one-off effect[20, 32] - Adjusted EBITDA guidance is set at €60-80 million, mitigating a large part of the approximate €90 million one-off effect[37] Strategic Developments & Partnerships - A major collaboration agreement was established with BMS in Neurodegeneration in June[29] - A Tech-Alliance was formed with Sandoz in May, and a second agreement was secured with the U S Department of Defense in July, validating Just – Evotec Biologics[29] - The company is progressing with pipeline building with partners, including Bayer, BMS, JingXin, Conba, Kazia, and Exscientia[29] - Together with Novo Nordisk, Evotec created "LAB eN²" to translate academic research in cardiometabolic diseases and rare disorders, initiating 65LAB in Singapore[29] Pipeline & Operations - PanOmics-based revenues experienced a growth of approximately 70%[43] - The company has >140 co-owned projects[45] - The construction of the J POD Toulouse is on track for completion in H2 2024[29, 49] ESG & Sustainability - Science Based Targets initiative (SBTi) has validated and approved near-term emission reduction targets[29, 54] - Evotec commits to 100% renewable electricity by 2026 and a 50 4% reduction of Scope 1 and 2 emissions by 2032[75]

| --- | --- | |---------------------------------|-------| | | | | | | | Emerging stronger | | | Pipeline building gaining speed | | Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Revenue Performance - Group revenues increased by 14% to €383.8 million in H1 2023, compared to €336.9 million in H1 2022, with like-for-like revenue growth also at 14%[4] - Total EVT Execute revenues rose by 2% to €356.6 million, while EVT Innovate revenues surged by 66% to €129.7 million in H1 2023[4] - Evotec reported a revenue of €383.835 million for the first half of 2023, an increase of 13.9% compared to €336.875 million in the same period of 2022[66] - Total revenues for the first half of 2023 amounted to €383,835k, representing a 14% increase compared to €336,875k in the same period of 2022[78][80] - Service fees and FTE-based research payments contributed €359,971k to total revenues, with a breakdown of €207,641k from Execute and €115,430k from Innovate[78] Financial Guidance - The company confirmed full-year 2023 revenue guidance of €750 – 790 million, with adjusted EBITDA guidance of €60 – 80 million[5] EBITDA and Profitability - Adjusted Group EBITDA for H1 2023 totaled €26.1 million, down from €33.6 million in H1 2022, impacted by a cyber-incident[4] - The company's Adjusted EBITDA for the first half of 2023 was €26.099 million, down from €33.636 million in the first half of 2022, reflecting a decrease of 22.4%[60] - Just – Evotec Biologics contributed an EBITDA of €8.5 million in H1 2023, with Q2 2023 showing a significant recovery to €20.0 million[26] - Net income for the first half of 2023 was a loss of €28.828 million, an improvement from a loss of €101.179 million in the same period of 2022[66] - The company’s total comprehensive income (loss) for the first half of 2023 was a loss of €18,478k, compared to a loss of €107,900k in the first half of 2022, reflecting a 82.9% improvement[69] Expenses and Costs - SG&A expenses increased by 31% to €88.2 million in H1 2023, driven by headcount growth to support business expansion[21] - Adjusted Group EBITDA for H1 2023 was €26.1 million, down from €33.6 million in H1 2022, impacted by a cyber-attack and higher management costs[25] - Cash flow from operating activities was €(5.2) million in H1 2023, a significant decline from €240.6 million in H1 2022, which was boosted by a $200 million upfront payment from BMS[32] Assets and Liabilities - Total assets increased by €44.0 million to €2,301.2 million as of 30 June 2023, with trade and other receivables rising by €30.7 million[37][38] - The company’s total financial assets as of June 30, 2023, were €1,008,060k, with cash and cash equivalents amounting to €459,752k[91] - The Group's total financial liabilities were €1,002,249k as of June 30, 2023, with loans and borrowings at €348,377k[92] - Total stockholders' equity decreased by 1% to €1,174.3 million as of 30 June 2023, with an equity ratio of 51.0%[46] Research and Development - Unpartnered R&D expenses are expected to be in the range of €60 – 70 million for FY 2023, consistent with €70 million in 2022[6] - Significant collaborations include a new agreement with Janssen for oncology therapies, with potential payments exceeding US$350 million over three years[12] - A milestone payment of €2 million was received from Bayer for the first patient dosed in a Phase I study of a kidney disease program[13] - R&D tax credits resulted in other operating income of €20.1 million in H1 2023, slightly up from €19.3 million in H1 2022[23] Cash Flow and Financing - Cash and cash equivalents increased to €459.752 million as of June 30, 2023, compared to €415.155 million at the end of 2022, representing a growth of 10.7%[64] - The company experienced a net cash inflow from financing activities of €10,480k in the first half of 2023, compared to a net outflow of €45,805k in the same period of 2022[68] - The company secured an unsecured loan facility of €150 million from the European Investment Bank to support R&D activities and the construction of a new production facility in Toulouse, France[74] Workforce and Growth - The workforce grew by 2.3% to 5,067 employees as of 30 June 2023, reflecting a net increase of 115 employees in the first half of the year[47] Market Performance - The company’s share price increased by 35% from the end of 2022 to June 30, 2023, significantly outperforming both the TecDAX and MDAX indices by more than 20%[62]

Exhibit 99.1 Notification of Major Holdings 2. Reason for notification (multiple reasons possible) 3. Details of person subject to the notification obligation | Natural person | | | | --- | --- | --- | | First name | Surname | Date of birth | Legal entity | Name including legal form (entity) | City of registered office | Country | | --- | --- | --- | | BlackRock, Inc. | New York, New York | United States of America (the) | Bundesanstalt für Finanzdienstleistungsaufsicht X Notification of Major Holdings or C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Evotec SE (OTCPK:EVOTF) Q4 2022 Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - Royal Bank of Canada Peter Verdult - Citi James Quigley - Morgan Stanley Steven Mah - Cowen Peter Welford - Jefferies Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator L ...

Evotec SE (OTCPK:EVOTF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - RBC Capital Markets Christian Ehmann - Warburg Research James Quigley - Morgan Stanley Derik de Bruin - Bank of America Peter Welford - Jefferies Joe Hedde ...

Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT 9M 2022 HIGHLIGHTS EVOTEC'S TOPLINE SUCCESS REFLECTS STRONG OVERALL DEMAND SHARED R&D PLATFORMS FOR HIGHER PROBABILITIES OF SUCCESS (POS) 2 4 MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS 4 PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY 4 COMMERCIAL LAUNCH OF NEXT-GENERAT ...